bosch49
Sep 25, 3:28 PM
$ACRV Copy and Pasted from Yahoo finance (part 1)
All that follows is just my opinion.... Agree that the current market cap appears quite low considering the potential. Per the CEO on the Cantor Global discussion, the market for the ACR-368 would be based on about 18,000 patients per year at 7 months treatment and
$30,000/month drug cost resulting by my calculation in >
$3B revenue per year and I gotta think that's at a huge gross margin, even sales at a percentage of this potential would be massive for this company versus its current capitalization. If the interim data in November is stellar, especially wrt Arm 4, then they can push for the breakthrough designation and rapid acceleration towards drug approval. That all said, this company needs more financing, so it remains to be seen if that means dilution (most likely) and how that impacts the value. In the near term, indications per CEO are that there may be some announcement in regard to the AP3 platform and potential partnerships
1 replies
